‹ ECARX
Ch 5 · The Story Behind the Numbers
Chapter 5 · Behind the Numbers
The quarter, in ECARX's own words.
Eight threads — financial discipline, the customer book diversifying, and the memory-cost cloud.
↓ scroll to read
✦ The bottom line
ECARX's Q1 6-K is ugly on the surface, encouraging underneath. Here's how management framed the quarter.
↓ the brief below
✦ Eight threads from the Q1 2026 6-K release
1
Revenue optics distorted by one-time fee.
Reported revenue of $131.5M (-22%) included tough comp from a $25M one-time software license in Q1 2025. Underlying platform sales were down only ~6%.
2
Gross margin expanded to 21.4%.
Up from 19.8% YoY — driven by price adjustments to pass through memory costs, and a mix shift toward high-end Pikes and Antora platforms.
3
R&D and SG&A both fell sharply.
R&D -32% YoY (resource prioritization + internal AI deployment). SG&A -24% YoY.
4
Third straight positive adjusted EBITDA.
+$4M in Q1 2026 vs. -$14.5M a year earlier — extends the streak of positive adj EBITDA to three quarters.
5
FY2026 guidance reiterated at $1.0-1.1B.
Despite the soft Q1, full-year revenue guidance was held — supported by backlog and accelerating commercial pipeline.
6
Volkswagen deal moved to industrialization.
VW partnership for Latin America (2027 launch) entered industrialization — a hard validation point for ECARX outside Geely.
7
May Mobility partnership announced.
ECARX joins a US autonomous ride-hail platform — small in dollars, large in narrative signaling for international diversification.
8
Memory costs are the swing factor for margins.
Management explicitly warned that gross margin and operating profitability will be negatively impacted by memory cost dynamics in coming quarters.
Source · 6-K · Q1 2026 unaudited financial results · Q1 2026 · Filed May 19, 2026
●
Read the whole story
Underlying margin progress, diversification momentum, but memory-cost overhang and tight cash deserve attention.
You just finished
Chapter 5 · BEHIND THE NUMBERS
The Story Behind the Numbers
you now read: reading the MD&A
Up next